14 Apr 2022 Update: Available Audit Reports and Planned Audits

21 Jan 2020

Nitrosamines – Risk evaluation

At the end of September EMA began a review under the Article 5(3) of Regulation (EC) No 726/2004 to provide guidance for MAHs on how to avoid nitrosamines in human medicines.

21 Jan 2020

GMP for Medicinal Cannabis – 29th of January

André Luz, the Director of Quality Assurance at Owlpharma, will be presenting a “GMP for Medicinal Cannabis” training on January 29th in collaboration with Formiventos.